Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlconHAM:2U3 +1.95%78 EV-to-EBIT is 42.24 as of Aug. 19, 2026, which is 27% above its 10-year median of 33.20. GuruFocus rates HAM:2U3 with a GF Score™ of 78/100 and a GF Value™ of €76.18 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Alcon ranks worse than 82.42% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alcon's Enterprise Value is €34,379 Mil.
Alcon's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €814 Mil. Therefore, Alcon's EV-to-EBIT for today is 42.24.
The historical rank and industry rank for Alcon's EV-to-EBIT or its related term are showing as below:
HAM:2U3'
s EV-to-EBIT Range Over the Past 10 Years
Min: -168.06 Med: 33.2 Max: 127.14
Current: 42.81
During the past 10 years, the highest EV-to-EBIT of Alcon was 127.14. The lowest was -168.06. And the median was 33.20.
HAM:2U3's EV-to-EBIT is ranked worse than 82.42% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.185
vs HAM:2U3: 42.81
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alcon's Enterprise Value for the quarter that ended in Jun. 2026 was €32,096 Mil.
Alcon's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €814 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon EV-to-EBIT Related Terms
Alcon EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Alcon's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Alcon's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alcon's EV-to-EBIT falls into.
Alcon's current Enterprise Value is €34,379 Mil.
Alcon's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €814 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon (HAM:2U3) has a EV-to-EBIT of 42.24 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alcon and its competitors. This is 27% above median its historical median of 33.20. According to the industry distribution chart, Alcon ranks #389 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 82.4%.
Is Alcon's EV-to-EBIT too high?
Alcon's current EV-to-EBIT of 42.24 is 27% above median its 10-year median of 33.20. The Medical Devices & Instruments industry median EV-to-EBIT is 19.19. Alcon's value of 42.24 is 120.2% above this industry median. Based on the distribution chart, Alcon ranks #389 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Alcon has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #389 out of 472 companies for EV-to-EBIT. This places Alcon in the lower half of its industry. The industry median EV-to-EBIT is 19.19. Alcon's value of 42.24 is 120.2% above this benchmark. While the company's 10-year median is 33.20 vs. the industry median of 19.19, Alcon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.19, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcon's current EV-to-EBIT of 42.24 is 120.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current EV-to-EBIT is 42.24, which is 27% above median its own 10-year median of 33.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (HAM:2U3) is currently considered Modestly Undervalued. The stock's GF Value™ is €76.18, compared to a current price of €63.92 — trading 16.1% below its estimated fair value. The current EV-to-EBIT is 42.24, which is 27% above median its 10-year median of 33.20 and 120.2% above the Medical Devices & Instruments industry median of 19.19. Alcon's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alcon (HAM:2U3), the current EV-to-EBIT is 42.24 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (HAM:2U3) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of €63.92 is trading 16.1% below its estimated GF Value™ of €76.18.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for HAM:2U3:
EV-to-EBIT: 42.24 (27% above median its 10-year median of 33.20)
GF Value™: €76.18 vs. price of €63.92 (16.1% below fair value)
Industry Position: 120.2% above the Medical Devices & Instruments median (#389 of 472)
No single metric tells the full story. See the HAM:2U3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
78GF Score
Get the complete analysis for HAM:2U3
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:2U3 has been successfully added to your 
